For the BCP-ALL and AML samples, over a 14-fold (5.7 pg/mL, p < 0.0001) and over 9-fold (25.5 pg/mL, p = 0.0199) increase in median GM-CSF levels was observed, respectively. This evidence concerns the gene CSF2 and acute myeloid leukemia.